EUVIMEDEUVIMED entdecken
Crossref

The phenomenon of remission in severe asthma: Potential of biologic therapy and unresolved issues of verification

V. V. Naumova, Е. К. Beltyukov, А. А. Shambatova, I. О. Nikiforova, A. I. Maksimova, P. А. Polinevskaya, M. V. Shvets

Meditsinskiy sovet = Medical Council · 14.07.2026 · (9) · 36-47

DOI: 10.21518/ms2026-164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Meditsinskiy sovet = Medical Council, online erschienen am 14.07.2026. Verfasst von V. V. Naumova und 6 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Biologics have shifted the treatment paradigm for severe asthma (SA), making clinico-functional remission a priority. However, the stability of this state and its predictors in real-world practice remain insufficiently studied.

Aim

To evaluate the frequency of sustained clinico-functional remission in SA patients and identify factors associated with long-term success. Materials and methods . This 30-month retrospective study analyzed data from a regional registry (Sverdlovsk Region) of SA patients treated with dupilumab, mepolizumab, benralizumab, or omalizumab. 4-component (no exacerbations, OCS withdrawal, ACT control, FEV1 stability) and 3-component (excluding FEV1) remissions were evaluated in rolling intervals (4–18, 12–24, and 18–30 months). Sustained remission required continuous fulfillment of criteria at all points (months 4, 12, 18, 24, and 30).

Results

Remission frequency in rolling intervals ranged from 1.7% to 45.1%. Sustained remission was achieved by 26.3% of patients. This group was significantly younger (46.5 vs 54.3 years; p = 0.014) and non-obese (BMI 23.1 vs 29.6 kg/m²; p = 0.001). Logistic regression identified elevated BMI as an independent predictor of remission failure (AUC 0.782; 95% CI: 0.652–0.912). A trend toward higher efficacy was noted with a disease duration < 12 years (p = 0.053). The highest proportion of sustained responses occurred with dupilumab (47.6%).

Conclusions

Sustained remission is achievable in 25% of SA patients. Excess body weight and long disease duration are key barriers, highlighting the need for early biologic initiation and metabolic correction.

Zitieren

APA

Naumova, V. V., Beltyukov, Е. К., Shambatova, А. А., Nikiforova, I. О., Maksimova, A. I., Polinevskaya, P. А., & Shvets, M. V. (2026). The phenomenon of remission in severe asthma: Potential of biologic therapy and unresolved issues of verification. Meditsinskiy sovet = Medical Council, 36-47. https://doi.org/10.21518/ms2026-164

Vancouver

Naumova VV, Beltyukov ЕК, Shambatova АА, Nikiforova IО, Maksimova AI, Polinevskaya PА, et al. The phenomenon of remission in severe asthma: Potential of biologic therapy and unresolved issues of verification. Meditsinskiy sovet = Medical Council. 2026:36-47. doi:10.21518/ms2026-164

BibTeX
@article{Naumova2026,
  author = {Naumova, V. V. and Beltyukov, Е. К. and Shambatova, А. А. and Nikiforova, I. О. and Maksimova, A. I. and Polinevskaya, P. А. and Shvets, M. V.},
  title = {The phenomenon of remission in severe asthma: Potential of biologic therapy and unresolved issues of verification},
  journal = {Meditsinskiy sovet = Medical Council},
  year = {2026},
  number = {9},
  pages = {36--47},
  doi = {10.21518/ms2026-164}
}
Kostenlos starten →